JMP Securities has initiated coverage on IDEAYA Biosciences Inc (IDYA) with a Market Outperform rating, marking the firm’s first assessment of the biotechnology company. Headquartered in South San Francisco, California, IDEAYA focuses on oncology-driven precision medicine and employs 131 full-time staff. The company went public on May 23, 2019, and is known for its innovative pipeline, including lead product candidates like darovasertib (PKC) and IDE397 (MAT2A).
As of now, IDEAYA's stock is priced at $33.82, with a market capitalization of $2.9 billion. The company's recent earnings performance shows a notable EPS of $1.33 for Q3 2025, significantly surpassing expectations of $-0.56, reflecting a 339.3% surprise. Upcoming earnings are anticipated on August 3, 2026, with estimated EPS of $-1.00 and revenue of $6.1 million.
Analyst ratings, such as the one from JMP, are derived from extensive research and can provide valuable insights. However, it's important to consider them alongside various factors, including company fundamentals and market trends. The current analyst consensus for IDEAYA is Buy, with 9 ratings for Strong Buy, 13 for Buy, and 3 for Hold.
This update provides insight into IDEAYA's positioning within the competitive biotechnology landscape, as it continues to develop targeted therapeutics based on molecular diagnostics.